NASDAQ: NMTCNeuroone Medical Technologies Corp Stock
$0.58+0.01 (+1.75%)
Updated Apr 17, 2025
NMTC Price
$0.58
Fair Value Price
N/A
Market Cap
$17.90M
52 Week Low
$0.40
52 Week High
$1.39
P/E
-2.23x
P/B
6.1x
P/S
2.91x
PEG
N/A
Dividend Yield
N/A
Revenue
$8.75M
Earnings
-$7.19M
Gross Margin
65.6%
Operating Margin
-82.15%
Profit Margin
-82.2%
Debt to Equity
1.21
Operating Cash Flow
-$7M
Beta
0.81
Next Earnings
May 12, 2025
Ex-Dividend
N/A
Next Dividend
N/A
NMTC Overview
NeuroOne Medical Technologies Corporation is developing thin film electrode technology for continuous electroencephalogram (cEEG) and stereoelectroencephalography (sEEG) recording, spinal cord stimulation, brain stimulation, and ablation solutions for patients suffering from epilepsy, Parkinson's disease, dystonia, essential tremors, chronic pain due to failed back surgeries, and other neurological disorders.NeuroOne Medical Technologies was founded in 2015 and is headquartered in Eden Prairie, MN.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine NMTC's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More
Zen Rating Component Grades
D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Medical Device
Industry Rating
C
NMTC
Ranked#41 of 102
Ranked#41 of 102
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $7.82 | A | |
| $22.79 | A | |
| $13.33 | A |
Be the first to know about important NMTC news, forecast changes, insider trades & much more!
NMTC News
Overview
Due Diligence Score
–
Industry Average (28)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how NMTC scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
NMTC is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
NMTC is poor value based on its book value relative to its share price (6.1x), compared to the US Medical Devices industry average (3.8x)
P/B vs Industry Valuation
NMTC is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more NMTC due diligence checks available for Premium users.
Valuation
NMTC price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-2.23x
Industry
41.14x
Market
27.98x
NMTC price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
6.1x
Industry
3.8x
NMTC is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
NMTC's financial health
Profit margin
Revenue
$6.3M
Net Income
$1.8M
Profit Margin
28.5%
NMTC's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
NMTC's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$6.5M
Liabilities
$3.6M
Debt to equity
1.21
NMTC's short-term assets ($5.71M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
NMTC's short-term assets ($5.71M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
NMTC's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
NMTC's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$208.0k
Investing
-$24.4k
Financing
-$509.3k
NMTC's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
NMTC vs Medical Device Stocks
Neuroone Medical Technologies Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.